BChE
Butyrylcholinesterase (BChE, EC 3.1.1.8) is a cholinesterase family enzyme that hydrolyzes a broad range of choline esters and other ester-containing substrates, contributing to cholinergic regulation as well as xenobiotic detoxification processes[1][2]. BChE is widely distributed in human tissues and plasma, where it participates in cholinergic transmission, ester metabolism, and the neutralization of toxic compounds including organophosphates and carbamates[1]. Mechanistically, BChE functions as a hydrolytic enzyme that can buffer acetylcholine metabolism when acetylcholinesterase (AChE) activity is reduced, thereby influencing cholinergic homeostasis[2]. In disease contexts, increasing evidence links BChE to neurodegenerative disorders, particularly Alzheimer’s disease (AD), where BChE activity and expression become more prominent during disease progression and are associated with late-stage cholinergic dysfunction[3][4]. Experimental studies therefore consider BChE an important therapeutic target and biomarker candidate for AD-related research[3][4]. Compared with the closely related isoform AChE, which primarily terminates synaptic acetylcholine signaling, BChE exhibits broader substrate specificity, distinct tissue distribution, and a stronger role in drug metabolism, detoxification, and non-neuronal physiological processes[1][2]. For experimental applications, selective BChE inhibitors are widely used to investigate cholinergic mechanisms and have been developed as pharmacological tools for evaluating therapeutic strategies in neurodegenerative disease models, with high selectivity over AChE considered a key design objective[3][4].
References:
- [1]. Hajimohammadi S, et al. New views on physiological functions and regulation of butyrylcholinesterase and potential therapeutic interventions. Front Mol Biosci. 2025 Jun 19;12:1625318. [Content Brief]
- [2]. Jovičić SM. Enzyme ChE, et al. Enzyme ChE, cholinergic therapy and molecular docking: Significant considerations and future perspectives. Int J Immunopathol Pharmacol. 2024 Jan-Dec;38:3946320241289013. [Content Brief]
- [3]. Brus B, et al. Discovery, biological evaluation, and crystal structure of a novel nanomolar selective butyrylcholinesterase inhibitor. J Med Chem. 2014 Oct 9;57(19):8167-79. [Content Brief]
- [4]. Zhou Y, et al. Discovery of Selective Butyrylcholinesterase (BChE) Inhibitors through a Combination of Computational Studies and Biological Evaluations. Molecules. 2019 Nov 20;24(23):4217. [Content Brief]
All Product Categories
-
BChE Related Products (223)
Related Products (223)
-
AChE-IN-102
0 ImagesCat. No.: HY-180243AChE-IN-102 (compound C8) is a potent, selective and competitive AChE inhibitor with a Ki of 7.55 nM and an IC50 of 15.25 nM. AChE-IN-102 shows selectivity over BuChE (IC50 = 21.15 nM, b>Ki = 6.17 nM). AChE-IN-102 can be used for Alzheimer’s disease research.
-
(+)-(3S)-ψ-Ribalinine
0 ImagesCat. No.: HY-N21824CAS No.: 155158-70-6(+)-(3S)-ψ-Ribalinine is an inhibitor of acetylcholinesterase (AChE) and butyrylcholinesterase (BChE), with an IC50 of 62.46 μM against electric eel acetylcholinesterase and an IC50 of 150.04 μM against equine butyrylcholinesterase. (+)-(3S)-ψ-Ribalinine can be used for the research of neurological disorders.
-
p38α-IN-13
0 ImagesCat. No.: HY-114422CAS No.: 3077831-12-7p38α-IN-13 is p38α MAPK, BChE and AChE inhibitor with IC50 values of 5.79, 16.24, 51.8 µM for p38α MAP, hBChE, hAChE, respectively. p38α-IN-13 has the potential for the research of Alzheimer’s disease.
-
AChE-IN-59
0 ImagesCat. No.: HY-157978CAS No.: 2957916-86-6AChE-IN-59 (compounds 3b) is an AChE inhibitor, with an IC50 value of 0.05 μM. AChE-IN-59 can inhibit the aggregation of Aβ1-42, protect nerve cells and penetrate the blood-brain barrier well. AChE-IN-59 can be used for the research of Alzheimer's disease (AD).
-
Desoxypeganine hydrochloride
0 ImagesCat. No.: HY-108048ACAS No.: 61939-05-7Synonyms: Deoxypeganine hydrochloride; Deoxyvasicine hydrochlorideDesoxypeganine (Deoxypeganine) hydrochloride, an alkaloid, is a potent and orally active cholinesterase (BChE and AChE) and selective MAO-A inhibitor, with IC50 values of 2, 17, and 2 μM, respectively. Desoxypeganine hydrochloride can be used for alcohol abuse research.
-
AChE/BChE-IN-3 hydrochloride
0 ImagesCat. No.: HY-146663ACAS No.: 2410992-69-5
-
MR2938
0 ImagesCat. No.: HY-149087CAS No.: 1044870-65-6
-
Icopezil
0 ImagesCat. No.: HY-105157CAS No.: 145508-78-7Synonyms: CP-118954Icopezil (CP-118954) is an orally active, selective AchE inhibitor with an IC50 of 0.33 nM. Icopezil increases acetylcholine levels in the brain and striatum of mammals, induces centrally mediated tremors and peripherally mediated salivation, and improves working memory performance in aged dogs. Icopezil serves as a parent compound for radioiodine-labeled acetylcholinesterase imaging agents. Icopezil is applicable to research related to Alzheimer's disease.
-
AP2238
0 ImagesCat. No.: HY-119292CAS No.: 553681-56-4AP2238 is a dual-function acetylcholinesterase (AChE) inhibitor with Ki values for human AChE (HuAChE) and butyrylcholinesterase (BuChE) of 21.7 and 48.9 μM respectively. AP2238 blocks the pro-fibrotic interaction between the peripheral site of AChE and Aβ, and can inhibit Aβ aggregation. AP2238 can be used for the research of Alzheimer's disease.
-
BChE-IN-10
0 ImagesCat. No.: HY-N10486CAS No.: 2185837-61-8BChE-IN-10 (compound 6) is a potent butyrylcholinesterase (BChE) mixed-type inhibitor with an IC50 value of 6.4 μM. BChE-IN-10 can be isolated from Bletilla striata. BChE-IN-10 can be used for the research of Alzheimer's disease (AD).
-
Chuanbeinone
0 ImagesCat. No.: HY-107272CAS No.: 103530-47-8Synonyms: 22-EpidelavinoneChuanbeinone (22-Epidelavinone) is an orally active alkaloid found in Fritillaria pallidiflora. Chuanbeinone shows cytotoxicity against mutiple cancer cells and can induces apoptosis and S phase arrest. Chuanbeinone downregulates Bcl-2, upregulates Bax, and activates caspase-3. Chuanbeinone exerts anti-inflammatory and antitussive effects by reducing pro-inflammatory cytokine (IL-1β, IL-6 and TNF-α) production and mRNA expression, and inhibiting TRIF-, MyD88-, NF-κB-, and MAPK-dependent signaling pathways. Chuanbeinone inhibits AChE and BChE with IC50 values of 7.7 and 0.7 μM. Chuanbeinone can be used for the researches of lung carcinoma, cough, inflammatory diseases.
-
CAI/II-IN-8
0 ImagesCat. No.: HY-161507CAS No.: 3036136-18-9CAI/II-IN-8 (Compound 8) is a hydrazide derivative based on 4-hydroxybenzaldehyde. CAI/II-IN-8 primarily targets human carbonic anhydrase isomerase I (hCA I) and II (hCA II) for inhibition (IC50 = 21.35 ± 0.39 nM (CA I); 7.12 ± 0.12 nM (CA II)). CAI/II-IN-8 inhibits AChE and BChE as well(IC50 = 46.27 ±0.75 nM (AChE); 43.38 ± 0.83 nM (BChE)). ..
-
S16–1029
0 ImagesCat. No.: HY-161331CAS No.: 2653349-51-8S16–1029 is a selective and orally active butyrylcholinesterase (BChE) inhibitor with IC50s of 11.35 nM and 48.1 nM for eqBChE and hBChE, respectively. S16–1029 could cross the blood-brain barrier (BBB) and reach the central nervous system (CNS). S16–1029 can be used for Alzheimer's disease (AD) research.
-
Multi-kinase-IN-10
0 ImagesCat. No.: HY-180892Multi-kinase-IN-10 (Compound IIIk) is a multi-kinase inhibitor. Multi-kinase-IN-10 exhibits significant calcium channel blocking activity, with its IC50 being 26.67 μM. Multi-kinase-IN-10 is a potent dual cholinesterase inhibitor, with its IC50 values for hAChE and hBuChE being 0.304 μM and 1.033 μM respectively. Multi-kinase-IN-10 has antioxidant and neuroprotective activities, and shows significant anti-amnesia activity. Multi-kinase-IN-10 can be used for research on Alzheimer's disease.
-
AChE/BChE-IN-37
0 ImagesCat. No.: HY-183760AChE/BChE-IN-37 is a blood-brain barrier-permeable AChE/BChE inhibitor, with an IC50 of 73.65 μM against electric eel-derived AChE and an IC50 of 82.93 μM against horse-derived BChE. AChE/BChE-IN-37 exhibits chelating activity towards Cu2+, Ca2+, Mg2+, Fe2+ and Zn2+. AChE/BChE-IN-37 interacts with HSP90AA1 and GSK-3β. AChE/BChE-IN-37 inhibits the self-induced aggregation of Aβ1-42. AChE/BChE-IN-37 suppresses LPS-induced NO production in cells. AChE/BChE-IN-37 can be used in research related to Alzheimer's disease and inflammatory diseases.
-
Drofenine
0 ImagesDrofenine (Cycloadiphene; Hexahydroadiphenine) is an brain-penetrant antispasmodic agent. Drofenine is a Kv2.1 channel inhibitor with human IC50 of 9.53 μM. Drofenine is a butyrylcholinesterase (BChE) inhibitor with Ki of 0.003 mM, and is a TRPV3 activator. Drofenine blocks Kv2.1-dependent potassium efflux, inhibits Kv2.1/JNK/NF-κB and IkBa/NF-kB signaling, suppresses Kv2.1 mRNA/protein expression. Drofenine suppresses oligomeric Aβ-induced microglial NLRP3 inflammasome activation and neuronal Tau hyperphosphorylation, improves cognitive impairment, promotes neurite outgrowth. Drofenine induces calcium influx in keratinocytes and exert cytotoxicity against keratinocytes. Drofenine ameliorates diabetic peripheral neuropathy -like pathology. Drofenine can be used for the researches of Alzheimer's disease, diabetic peripheral neuropathy and smooth muscle spasm.
-
AChE/BuChE/MAO-B-IN-2
0 ImagesCat. No.: HY-149090CAS No.: 3044829-88-8AChE/BuChE/MAO-B-IN-2 (compound 4b) is a potent AChE/BuChE inhibitor and showed good blood brain barrier (BBB) permeability in vitro with an IC50 value of 5.3 μM, 12.4 μM, 1.9±0.08 μM, for AChE, BuChE, huMAO-B, respectively. AChE/BuChE/MAO-B-IN-2 (compound 4b) can inhibit excess AChE/BuChE in Alzheimer's disease (AD) brain. AChE/BuChE/MAO-B-IN-2 (compound 4b) can be used in anti-Alzheimer's research.
-
BuChE-IN-4
0 ImagesCat. No.: HY-146687CAS No.: 2499490-52-5BuChE-IN-4 (Compound C6) is a potent inhibitor of BuChE with an IC50 of 7.7 nM. BuChE-IN-4 exhibits mild antioxidant capacity, nontoxicity, lipophilicity and neuroprotective activity.
